Thyroid Hormone Replacement After Coronary Artery Bypass Grafting for Patients With Subclinical Hypothyroidism
Recruiting
N/A
Interventional Study
Subclinical Hypothyroidism
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 19 – 90
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 338 (estimated)
- Sponsor
- Seoul National University Bundang Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this clinical trial is to find out whether levothyroxine reduces complications and improves the prognosis of patients with subclinical hypothyroidism (SCH) undergoing coronary artery bypass grafting (CABG).
The main questions this study aims to answer are:
• Does levothyroxine reduce major adverse cardiovascular events (MACE), including cardiovascular death, nonfatal myocardial infar…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Eligibility Criteria
* Adults aged 19 to 90 years.
* Patients scheduled to undergo coronary artery bypass graft (CABG) surgery.
* Subclinical hypothyroidism (SCH), defined as a normal free thyroxine (free T4) level and a thyroid-stimulating hormone (TSH) level greater than 4 μIU/mL, based on testin…
Contacts